60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Kronos Advanced Technologies Inc Maintains Leadership As The First Public Company To Embrace Shiba Inu: A Leap Into The Future Of E-Commerce Payments
June 10, 2024 15:01 ET
|
Kronos Advanced Technologies Inc.
Los Angeles, CA , June 10, 2024 (GLOBE NEWSWIRE) -- Kronos Advanced Technologies Inc. (OTC: KNOS), a leading innovator in air purification solutions, is thrilled to announce the acceptance of Shiba...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
June 06, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
June 03, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announces that the U.S. Food and Drug Administration (FDA) has provided...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024 07:05 ET
|
uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...
New AAMI Guidance on Combination Products and FDA CGMPs
May 30, 2024 08:47 ET
|
AAMI
Arlington, Virginia, May 30, 2024 (GLOBE NEWSWIRE) -- As the breadth and scope of combination products around the world continues to ramp up, are U.S. manufacturers equipped with the best design...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
May 28, 2024 16:30 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
May 23, 2024 12:38 ET
|
The Rosen Law Firm PA
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
May 16, 2024 07:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...